Background
- 55 y/o M with complaints of blurred vision after each cancer treatment that resolves within a few days. He had two prior cycles of treatment and experienced the same vision symptoms each time.
PMH: Recurrent cutaneous melanoma on dabrafenib (BRAF Inhibitor) and trametinib (MEK Inhibitor)